Objective To evaluate the efficacy and adverse events of R - FCD. FCD, R - CHOP and CHOP in treatment of patients with indolent lymphoma. Methods Seventy eight cases diagnosed as indolent lymphoma were randomly divided into FCD and CHOP groups whether addition of Rituximah was hased on their economic status, and chemotherapy was carried out at least for 4 courses in patients of 4 groups for observation of rates of CR and OR, DFS and adverse events. Results The regimen combined with Rituximah can increase CR rate. and it can also raise DFS. The difference among rates of CR and OR and DFS in treatment with R - FCD and R - CHOP was not significant. The difference in OR rate of FCD therapy in comparison with that of CHOP therapy was not significant, but its CR rate was significantly raised and it can improve DFS. Conclusion Rituximab combined with chemotherapy can significantly improve the efficacy of treatment for cases of indolent lymphoma with less adverse events. FCD therapy in comparison with CHOP can significantly increase CR rate. but its hone marrow suppression was more serious.%目的 观察不同化疗方案对惰性淋巴瘤的治疗的疗效及副作用.方法 78例初治惰性淋巴瘤病人随机分成氟达拉滨+环磷酰胺+地塞米松(FCD)组和环磷酰胺+长春新碱+表阿霉素+强的松(CHOP)组,根据病人的经济状况加用利妥昔单抗[氟达拉滨+环磷酰胺+地塞米松联合利妥昔单抗(R-FCD)组,环磷酰胺+长春新碱+表阿霉素+强的松联合利妥昔单抗(R-CHOP)组].完成最少4个疗程化疗方案,观察4组病人的完全缓解率、有效率、无疾病进展生存时间及不良反应.结果 含利妥昔单抗的方案能明显提高完全缓解率,并能提高无疾病进展生存时间.使用利妥昔单抗的FCD和CHOP方案完全缓解率、缓解率和无疾病进展生存时间均无显著性差异.FCD方案与CHOP方案比较,总缓解率无明显差异,但完全缓解率明显提高,且能延长无疾病进展生存时间.结论 利妥昔单抗联合化疗能明显提高惰性淋巴瘤治疗疗效,不良反应较小.FCD方案较CHOP方案能提高完全缓解率,但骨髓抑制作用较大.
展开▼
